Download PDF
PRESS RELEASE

April 4, 2024

Alnylam Receives Positive Reimbursement Recommendation From The Canadian Agencies For Drugs And Technology In Health (CADTH) For AMVUTTRA®
Download PDF
PRESS RELEASE

May 18, 2022

Alnylam launches third RNAi therapeutic approved in Canada
Download PDF
PRESS RELEASE

March 17, 2021

Alnylam Wins Prestigious Prix Galien Canada Award for Best Innovative Product with First-Ever Health Canada-Approved RNAi Therapeutic, ONPATTRO® (patisiran)
Download PDF
PRESS RELEASE

July 23, 2019

Alnylam launches the first ever RNAi therapeutic approved in Canada
Download PDF
PRESS RELEASE

May 15, 2019

Harnessing RNAi: Alnylam Pharmaceuticals is conquering rare diseases one drug at a time
Download PDF
PRESS RELEASE

November 26, 2018

Alnylam Pharmaceuticals: Bringing groundbreaking gene silencing therapies to Ontario.
Download PDF
PRESS RELEASE

September 24, 2018

Alnylam Pharmaceuticals Receives Priority Review in Canada for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Polyneuropathy

GET IN TOUCH

Questions, concerns, or comments about this content? We encourage you to reach out to our team.

Contact us ›

OTHER INQUIRIES

Media: media@alnylam.com   
Investor Relations: investors@alnylam.com   
General: info@alnylam.ca